A Multicenter, Open Label, Phase II Study of Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe Study).
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Dec 2016
At a glance
- Drugs Bendamustine (Primary) ; Ibritumomab tiuxetan; Rituximab
- Indications Follicular lymphoma
- Focus Therapeutic Use
- Acronyms Fol-BRITe
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
- 04 May 2012 Additional lead trial investigators identified as reported by ClinicalTrials.gov.
- 27 Apr 2012 Planned end date changed from 1 Dec 2013 to 1 Dec 2020 as reported by ClinicalTrials.gov.